These include reducing nitric oxide (NO) [45] bioavailability, activating NADPH oxidase [46,47], and stimulating pro-inflammatory signaling pathways such as NF-κB and MAPK could exacerbate systemic inflammation, potentially contributing to the progression of CKD and related complications [42,48]. This evidence concerns the gene FMO5 and chronic kidney disease.